TB‑500 (Thymosin Beta‑4 Peptide) Profile

TB‑500 is a synthetic heptapeptide (Ac‑LKKTETQ) representing the active fragment of the naturally occurring signalling protein thymosin beta‑4 (Tβ4). It is engineered to mimic the biological actions of Tβ4 — a peptide involved in cell migration, wound healing, angiogenesis (formation of new blood vessels), inflammation modulation, and tissue regeneration. Because it corresponds to the active region of Tβ4, TB‑500 is widely discussed in regenerative medicine, sports recovery communities, and preclinical research for its capacity to support repair processes and flexibility, although rigorous clinical evidence in humans remains limited. It has no FDA approval for therapeutic use, and its human safety and efficacy have not been confirmed in controlled clinical trials. TB‑500 and related thymosin beta‑4 derivatives are prohibited in professional sports under anti‑doping regulations due to their potential performance‑enhancing effects and detection in biological samples. (Wikipedia)

Mechanism of Action & Effects (Research Context)
TB‑500 is thought to:

  • Promote cell migration and actin regulation to facilitate tissue repair. (Siam Clinic Thailand)
  • Enhance angiogenesis, improving blood flow and nutrient delivery to injury sites. (Swolverine)
  • Modulate inflammation by shifting immune responses toward resolution pathways. (GlobalRPH)
  • Support collagen production and extracellular matrix remodeling, aiding structural recovery. (Medium)

Most supporting data derive from preclinical studies (animal or in vitro) rather than controlled human trials. (Innerbody)

Uses & Applications (Investigational/Experimental)
TB‑500 is promoted in research and community settings for:

  • Accelerating healing of muscles, tendons, ligaments, and skin injuries. (HubMedEd)
  • Supporting post‑surgical recovery and joint mobility. (Siam Clinic Thailand)
  • Reducing localized inflammation. (Swolverine)
  • Potential cardiac or ocular tissue repair in specialized research studies. (Dr.Oracle)

Safety & Regulatory Notes
TB‑500 is not approved by major regulatory agencies for any medical indication, and products sold online vary widely in purity and composition. Its use can carry risks related to unverified manufacture, mislabelling, or unintended biological effects. Professional medical supervision is essential in any investigational context. (The Washington Post)

Typical Experimental Dosing Chart (Community / Research‑Oriented)
| Phase | Dose | Frequency | Route | Notes |
| Loading Phase | 2.0–5.0 mg | 2×/week | Subcutaneous or IM | Early ramp‑up; experimental only (Siam Clinic Thailand) |
| Weekly Total | 4–10 mg/week | 1–3 injections/week | Subcutaneous/IM | Common in community protocols (not clinical) (Prime IV Hydration & Wellness) |
| Maintenance Phase | 2–6 mg | Every 1–2 weeks | Subcutaneous/IM | After initial period or symptom improvement (Cellgenic) |

References (APA):
TB‑500. (2025). Wikipedia. https://en.wikipedia.org/wiki/TB-500 (Wikipedia)
TB‑500 Peptide | Healing & Flexibility. (n.d.). Paragon Sports Medicine. (Paragon Sports Medicine)
TB 500 Peptide: How It Supports Tissue Repair and Flexibility. (2025, July 31). HubMedEd. (HubMedEd)
TB‑4 and TB‑500 Peptide Therapy | What to Know in 2025. (2025). Innerbody. (Innerbody)
BPC‑157 & TB‑500: Background, Indications, Efficacy, and Safety. (2025). GlobalRPh. (GlobalRPH)
TB 500 (TB500) Peptide Guide. (2024). Prime IV Hydration. (Prime IV Hydration & Wellness)